ID   PC3-MM2
AC   CVCL_4885
SY   PC3MM2; PC-3MM2; PC-3 MM2; PC-3M-MM2
DR   BTO; BTO:0005071
DR   cancercelllines; CVCL_4885
DR   KCLB; 80021
DR   Wikidata; Q54938569
RX   CelloPub=CLPUB00698;
RX   PubMed=11304728;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (PubMed=11304728).
CC   Derived from site: Metastatic; Bone; UBERON=UBERON_0002481.
ST   Source(s): PubMed=11304728
ST   Amelogenin: X
ST   D13S317: 11
ST   D18S51: 14,15
ST   D21S11: 29,31.2
ST   D3S1358: 16
ST   D5S818: 13
ST   D7S820: 8,11
ST   D8S1179: 13
ST   FGA: 24
ST   vWA: 17
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_9555 ! PC-3M
SX   Male
AG   62Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 18
//
RX   CelloPub=CLPUB00698;
RA   van Bokhoven A.;
RT   "Models for prostate cancer. Molecular characterization and critical
RT   appraisal of human prostate carcinoma cell lines.";
RL   Thesis PhD (2004), Katholieke Universiteit Nijmegen, Netherlands.
//
RX   PubMed=11304728; DOI=10.1002/pros.1045;
RA   van Bokhoven A., Varella-Garcia M., Korch C.T., Hessels D., Miller G.J.;
RT   "Widely used prostate carcinoma cell lines share common origins.";
RL   Prostate 47:36-51(2001).
//